BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 22951242)

  • 21. MAOIs and depression treatment guidelines.
    Thase ME
    J Clin Psychiatry; 2012 Jul; 73(7):e24. PubMed ID: 22901357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment-resistant depression: definition and treatment approaches.
    Nierenberg AA; Amsterdam JD
    J Clin Psychiatry; 1990 Jun; 51 Suppl():39-47; discussion 48-50. PubMed ID: 2112132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug combinations in the treatment of refractory depression: a review.
    Stern SL; Mendels J
    J Clin Psychiatry; 1981 Oct; 42(10):368-73. PubMed ID: 6116699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ketamine and Monoamine Oxidase Inhibitor Combination: Utility, Safety, Efficacy?
    Bottemanne H; Bonnard E; Claret A; Petit AC; Gaillard R; Fossati P
    J Clin Psychopharmacol; 2020; 40(6):636-638. PubMed ID: 33009225
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment with selective and reversible monoamine oxidase inhibitors in depressed patients: is there a biological effect proportional to the dose?].
    Radat F; Berlin I; Varoquaux O; Ferreri M; Puech A
    Ann Med Psychol (Paris); 1996 Jun; 154(3):204-6. PubMed ID: 8766502
    [No Abstract]   [Full Text] [Related]  

  • 26. Drugs for depression.
    Med Lett Drugs Ther; 2016 Jul; 58(1498):85-90. PubMed ID: 27348144
    [No Abstract]   [Full Text] [Related]  

  • 27. Trimipramine and maprotiline plasma levels during combined treatment with moclobemide in therapy-resistant depression.
    König F; Wolfersdorf M; Löble M; Wössner S; Hauger B
    Pharmacopsychiatry; 1997 Jul; 30(4):125-7. PubMed ID: 9271778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tyramine and new monoamine oxidase inhibitor drugs.
    Simpson GM; de Leon J
    Br J Psychiatry Suppl; 1989 Oct; (6):32-7. PubMed ID: 2695125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Drug treatment strategies in antidepressive drug therapy-resistant depression].
    Möller HJ
    Klin Wochenschr; 1991 Jun; 69(9):413-5. PubMed ID: 1681133
    [No Abstract]   [Full Text] [Related]  

  • 30. What is the bottom line for dietary guidelines when taking monoamine oxidase inhibitors?
    Marcason W
    J Am Diet Assoc; 2005 Jan; 105(1):163. PubMed ID: 15635366
    [No Abstract]   [Full Text] [Related]  

  • 31. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
    Volz HP; Gleiter CH; Möller HJ
    Nervenarzt; 1996 May; 67(5):339-47. PubMed ID: 9005342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Which antidepressant?
    Benaim S
    Br J Clin Pract; 1990 May; 44(5):196-200. PubMed ID: 2390444
    [No Abstract]   [Full Text] [Related]  

  • 33. Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depression.
    Thase ME
    J Clin Psychiatry; 2006 Apr; 67(4):671-2. PubMed ID: 16669733
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of the cardiac-impaired depressed patient. Part I: General considerations, heterocyclic antidepressants, and monoamine oxidase inhibitors.
    Goldstein MG; Guttmacher LB
    Psychiatr Med; 1988; 6(3):1-33. PubMed ID: 3062672
    [No Abstract]   [Full Text] [Related]  

  • 35. Pindolol augmentation of tranylcypromine in psychotic depression.
    Kraus RP
    J Clin Psychopharmacol; 1997 Jun; 17(3):225-6. PubMed ID: 9169970
    [No Abstract]   [Full Text] [Related]  

  • 36. Strategies for fluoxetine-MAOI combination therapy.
    Peterson GN
    J Clin Psychiatry; 1991 Feb; 52(2):87-8. PubMed ID: 1993642
    [No Abstract]   [Full Text] [Related]  

  • 37. Refractory depression treated with high doses of monoamine oxidase inhibitor.
    Guze BH; Baxter LR; Rego J
    J Clin Psychiatry; 1987 Jan; 48(1):31-2. PubMed ID: 3804984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules.
    Azzaro AJ; Ziemniak J; Kemper E; Campbell BJ; VanDenBerg C
    J Clin Pharmacol; 2007 Oct; 47(10):1256-67. PubMed ID: 17715422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MAOI-narcotic interactions.
    Gratz SS; Simpson GM
    J Clin Psychiatry; 1993 Nov; 54(11):439. PubMed ID: 7903665
    [No Abstract]   [Full Text] [Related]  

  • 40. [Future directions for drug treatment of drug-resistant depression].
    Isometsä E; Syvälahti E
    Duodecim; 2004; 120(7):821-30. PubMed ID: 15154302
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.